

Table SI. Clinical features

Pat. No.	Skin features	Sex	Age at diagnosis, years	Age at start of MPC, years	Treatment course, n	Smoker	Previous treatment	Concomitant treatment	Mepacrine Initial (max) daily dose, mg	Duration of treatment, months	Response/RCLASI at start/at time of best response	Side-effects	Follow-up <sup>a</sup>
1	SCLE	M	62	73	1	Yes	HCQ	HCQ	100 (100)	8	CR		8
2	SCLE	F	44	50	2	Yes	HCQ	HCQ	100 (100)	4	10/0 PR	Elevated liver enzymes, rash	39
3	SCLE	M	41	42	3	Yes	CS (SYS) HCQ	CS (TOP) HCQ	200 (200)	28	PR (TRANS) 22/8		144
4	SCLE	F	46	54	4	Yes	CS (SYS) HCQ CQ	CS (SYS) CS (SYS) CS (TOP)	100 (100)	22	NR 9/9		107
5	LET	F	40	49	5	Yes	CS (SYS) MPC HCQ	CQ	100 (100)	1	NA NA	Pruritus	15
6	DLE	F	30	39	7	Yes	CQ HCQ acitretin azathioprine thalidomide	HCQ HCQ CS (TOP)	100 (100) 100 (100) 150	8 50	CR (FU) 6/0 PR 8/0		102
7	DLE	F	30	44	8	Yes	HCQ MPC acitretin azathioprine thalidomide	HCQ	100 (100)	5	PR (TRANS) 10/3		102
8	DLE	F	20	22	10	History of smoking	HCQ	HCQ	100 (100)	31	PR (TRANS) 6/3	Discoloration of the skin	12
9	DLE	F	21	23	11	Yes	HCQ	HCQ	200 (200)	6	PR 6/5	Discoloration of the skin, photosensitivity	105
10	DLE	F	18	31	13	History of smoking	HCQ MPC CQ	HCQ CQ	100 (100) 200 (200)	9 1	PR 5/2 NA NA	Discoloration of the skin Fatigue, weight loss	82

<sup>a</sup>Follow-up time in months since (first) initiation of Mepacrine.

CQ: chloroquine; CR: complete remission; PR (FU): complete remission followed by flare-ups; CS (SYS): systemic corticosteroids; CS (TOP): topical corticosteroids; DLE: discoid lupus erythematosus; HCQ: hydroxychloroquine; LET: tumid lupus erythematosus; NA: not applicable; NR: non-responder; PR: partial response; PR (TRANS): transitory partial response; RCLASI: revised cutaneous lupus erythematosus disease area and severity index; SCLE: subacute cutaneous lupus erythematosus.